Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Magnhild Sandberg-Wollheim

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Expert Review of Neurotherapeutics|April 28, 2005
Interferon-beta1a treatment for multiple sclerosisMagnhild Sandberg-Wollheim
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 12, 2011
Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapyMagnhild Sandberg-Wollheim, Enrica Alteri, Margaretha Stam Moraga, et al.
Journal of Neurology|March 22, 2005
Predicting the outcome of optic neuritis: evaluation of risk factors after 30 years of follow-upPetra Nilsson, Elna-Marie Larsson, Pia Maly-Sundgren, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 14, 2011
The risk of malignancy is not increased in patients with multiple sclerosis treated with subcutaneous interferon beta-la: analysis of data from clinical trial and post-marketing surveillance settingsMagnhild Sandberg-Wollheim, Gabrielle Kornmann, Dorina Bischof, et al.
Current Medical Research and Opinion|August 15, 2009
Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining commandMark S Freedman, Bruce Cohen, Suhayl Dhib-Jalbut, et al.
Therapeutic Advances in Neurological Disorders|February 23, 2011
Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up studyBernard Uitdehaag, Cris Constantinescu, Peter Cornelisse, et al.
Archives of Neurology|May 11, 2005
Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE StudySteven R Schwid, John Thorpe, Mohammad Sharief, et al.
International Journal of MS Care|March 7, 2018
Pregnancy Outcomes from the Branded Glatiramer Acetate Pregnancy DatabaseMagnhild Sandberg-Wollheim, Orit Neudorfer, Augusto Grinspan, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|June 14, 2017
Prognostic factors for long-term outcomes in relapsing-remitting multiple sclerosisAnthony L Traboulsee, Peter Cornelisseª, Magnhild Sandberg-Wollheim, et al.
The Lancet. Neurology|May 5, 2009
NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trialPer Soelberg Sorensen, Svein Ivar Mellgren, Anders Svenningsson, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Expert Review of Neurotherapeutics|April 28, 2005
Interferon-beta1a treatment for multiple sclerosisMagnhild Sandberg-Wollheim
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 12, 2011
Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapyMagnhild Sandberg-Wollheim, Enrica Alteri, Margaretha Stam Moraga, et al.
Journal of Neurology|March 22, 2005
Predicting the outcome of optic neuritis: evaluation of risk factors after 30 years of follow-upPetra Nilsson, Elna-Marie Larsson, Pia Maly-Sundgren, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 14, 2011
The risk of malignancy is not increased in patients with multiple sclerosis treated with subcutaneous interferon beta-la: analysis of data from clinical trial and post-marketing surveillance settingsMagnhild Sandberg-Wollheim, Gabrielle Kornmann, Dorina Bischof, et al.
Current Medical Research and Opinion|August 15, 2009
Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining commandMark S Freedman, Bruce Cohen, Suhayl Dhib-Jalbut, et al.
Therapeutic Advances in Neurological Disorders|February 23, 2011
Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up studyBernard Uitdehaag, Cris Constantinescu, Peter Cornelisse, et al.
Archives of Neurology|May 11, 2005
Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE StudySteven R Schwid, John Thorpe, Mohammad Sharief, et al.
International Journal of MS Care|March 7, 2018
Pregnancy Outcomes from the Branded Glatiramer Acetate Pregnancy DatabaseMagnhild Sandberg-Wollheim, Orit Neudorfer, Augusto Grinspan, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|June 14, 2017
Prognostic factors for long-term outcomes in relapsing-remitting multiple sclerosisAnthony L Traboulsee, Peter Cornelisseª, Magnhild Sandberg-Wollheim, et al.
The Lancet. Neurology|May 5, 2009
NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trialPer Soelberg Sorensen, Svein Ivar Mellgren, Anders Svenningsson, et al.
Pageof 2